UK biopharma Orchard Therapeutics has added Alicia Secor, former President and CEO of Juniper Pharmaceuticals, to its Board of Directors.
Ms Secor brings more than 25 years of life sciences leadership and commercial product expertise with a particular focus in rare disease and other areas of unmet need.
“We are thrilled to welcome Alicia to our board of directors at this pivotal time in Orchard’s development,” said Mark Rothera, Orchard’s President and CEO.
“Alicia’s experience in leading product development from clinical trials to regulatory approvals and commercialization will be incredibly valuable to Orchard as we begin preparations for regulatory filings for our lead programs.
“We believe Alicia’s strategic insights and dedication to patients will support our mission to transform the lives of patients with rare diseases as Orchard advances as a global leader in gene therapy.”
During her time at the head of Juniper, Ms Secor led the company’s successful turnaround strategy which resulted in a sale to Catalent in August 2018.
Prior to this role, she held several leadership positions in the life sciences industry, including COO at Zafgen, Senior Vice President and COO at Synageva BioPharma Corp, and roles of increasing responsibility at Genzyme.
She said: “I look forward to working with Orchard’s executive leadership team and board of directors to help bring the promise of transformative ex vivo lentiviral gene therapy to patients and families across multiple rare disease categories.”